文献速递前列腺癌

基于18F-PSMA PET/CT在前列腺癌根治术中行淋巴结清扫的前瞻性随机研究中期结果

Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-09-25

该前瞻性随机研究纳入120例中高危前列腺癌患者,评估基于18F-PSMA PET/CT结果决定是否行盆腔淋巴结清扫的可行性。PSMA PET/CT检测淋巴结转移的敏感性76.5%、特异性86.8%、准确性65.0%、PPV 92.0%、NPV 84.3%。PSMA阴性患者中,清扫组与未清扫组PFS和PSA持续无显著差异,但清扫组手术时间、住院时间更长且并发症率更高。

要点

  • PSMA PET/CT对淋巴结转移具有高特异性和高阴性预测值。
  • PSMA阴性患者省略淋巴结清扫未影响肿瘤学结果。
  • 淋巴结清扫增加手术时间、住院时间和并发症率。

核心结论

  • PSMA PET/CT检测淋巴结转移具有高特异性和阴性预测值。
  • PSMA PET/CT判定的淋巴结阴性患者可能无需行淋巴结清扫,未清扫者建议密切随访。

研究设计与样本

  • 前瞻性随机研究,纳入活检确诊的中危或高危前列腺癌患者,排除远处转移或既往内分泌治疗者。
  • 所有患者行18F-PSMA PET/CT,有淋巴结转移者归入A组;无淋巴结转移者按1:1随机分为B组和C组。
  • 所有患者行机器人辅助根治性前列腺切除术,A组和B组行盆腔淋巴结清扫,C组不行。
  • 主要结局为PSMA PET/CT检测淋巴结转移的准确性和肿瘤学结果。
  • 2022年9月至2023年8月共纳入120例前列腺癌患者。

主要发现

  • PSMA PET/CT检测淋巴结转移的敏感性76.5%、特异性86.8%、准确性65.0%、阳性预测值92.0%、阴性预测值84.3%。
  • B组与C组在临床参数、无进展生存期或PSA持续方面无显著差异。
  • 行淋巴结清扫的患者手术时间更长、住院时间更长、并发症率更高。

临床怎么用

  • 可利用PSMA PET/CT的高阴性预测值识别可安全省略淋巴结清扫的淋巴结阴性患者。
  • 对PSMA PET/CT判定淋巴结阴性而未行清扫的患者建议密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pelvic lymph node dissection (PLND) is integral to prostate cancer staging, but its therapeutic value remains debated. PSMA PET/CT has shown high accuracy in detecting lymph node metastasis (LNM). This study evaluates the feasibility of performing PLND based on PSMA PET/CT findings during robotic-assisted radical prostatectomy (RARP). METHODS: In this prospective, randomized study, biopsy-confirmed prostate cancer (PCa) patients with intermediate or high risk were enrolled. Patients with distant metastasis or prior endocrine therapy were excluded. All underwent 18F-PSMA PET/CT imaging, and those with LNM were assigned to Group A. Patients without LNM were randomized in a 1:1 ratio into Groups B and C. All patients underwent RARP and Groups A and B with PLND while Group C without. The primary outcomes were PSMA PET/CT accuracy in detecting LNM and oncological results. This trial is registered with the Chinese Clinical Trial Registry (ChiCTR2200063256). RESULTS: Between September 2022 and August 2023, 120 PCa patients were enrolled. The sensitivity, specificity, accuracy, positive predictive value (PPV), and NPV of PSMA PET/CT were 76.5%, 86.8%, 65.0%, 92.0%, and 84.3%. There were no significant differences in clinical parameters, progression-free survival (PFS) or PSA persistence between Groups B and C. However, PLND patients had longer surgical times, hospital stays, and higher complication rates. CONCLUSIONS: PSMA PET/CT offers high specificity and NPV in detecting LNM.LND may be unnecessary for node-negative patients identified by PSMA PET/CT, with close follow-up recommended for those not undergoing LND.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Jia Z, Liu Q, Liu K, et al. Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study. Prostate Cancer Prostatic Dis. 2025. PMID: 40999072. doi:10.1038/s41391-025-01029-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。